PharmaCyte Biotech (PMCB) Retained Earnings (2011 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Retained Earnings of $182.7 million for Q2 2026, up 0.68% year-over-year from $181.5 million in Q2 2025, and little changed quarter-over-quarter from $183.1 million in Q1 2026.
PharmaCyte Biotech (PMCB) Retained Earnings (2011 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Retained Earnings for 16 consecutive years, with $182.7 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Retained Earnings rose 0.68% year-over-year to $182.7 million; the TTM figure through Apr 2026 stood at $182.7 million (up 0.68% YoY), while the FY2026 annual figure was $182.7 million, up 0.68% from the prior year.
- Retained Earnings held at $182.7 million in Q2 2026 per PMCB's latest filing, from $183.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at $202.2 million in Q1 2023 and bottomed at $180.6 million in Q4 2025.
- Historically, Retained Earnings has averaged $190.7 million across 5 years, with a median of $187.3 million in 2024.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 77.05% — and 2024, when it fell 8.36%.
- PharmaCyte Biotech's Retained Earnings stood at $201.6 million in 2022, then fell by 3.97% to $193.6 million in 2023, then decreased by 6.32% to $181.4 million in 2024, then decreased by 0.41% to $180.6 million in 2025, then grew by 1.17% to $182.7 million in 2026.
- Business Quant data shows PMCB's Retained Earnings at $182.7 million in Q2 2026, $183.1 million in Q1 2026, and $180.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | 182.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 182.72 Mn |
| Jan 31, 2026 | 183.14 Mn |
| Oct 31, 2025 | 180.61 Mn |
| Jul 31, 2025 | 181.55 Mn |
| Apr 30, 2025 | 181.49 Mn |
| Jan 31, 2025 | 181.43 Mn |
| Oct 31, 2024 | 181.35 Mn |
| Jul 31, 2024 | 182.72 Mn |
| Apr 30, 2024 | 185.33 Mn |
| Jan 31, 2024 | 189.22 Mn |
| Oct 31, 2023 | 193.59 Mn |
| Jul 31, 2023 | 198.64 Mn |
| Apr 30, 2023 | 202.23 Mn |
| Jan 31, 2023 | 202.23 Mn |
| Oct 31, 2022 | 201.60 Mn |
| Jul 31, 2022 | 201.59 Mn |
| Apr 30, 2022 | 201.58 Mn |
| Jan 31, 2022 | 201.57 Mn |
| Oct 31, 2021 | 201.56 Mn |
| Jul 31, 2021 | 114.17 Mn |